|
1
|
Unni KK: Osteosarcoma of bone. J Orthop
Sci. 3:287–294. 1998. View Article : Google Scholar
|
|
2
|
Fuchs B and Pritchard DJ: Etiology of
osteosarcoma. Clin Orthop Relat Res. 40–52. 2002. View Article : Google Scholar
|
|
3
|
Bernier J, Hall EJ and Giaccia A:
Radiation oncology: a century of achievements. Nat Rev Cancer.
4:737–747. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jung M and Dritschilo A: NF-kappaB
signaling pathway as a target for human tumor radiosensitization.
Semin Radiat Oncol. 11:346–351. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Habraken Y and Piette J: NF-kappaB
activation by double-strand breaks. Biochem Pharmacol.
72:1132–1141. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
McKenna WG and Muschel RJ: Targeting tumor
cells by enhancing radiation sensitivity. Genes Chromosomes Cancer.
38:330–338. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kim HJ, Hawke N and Baldwin AS: NF-kappaB
and IKK as therapeutic targets in cancer. Cell Death Differ.
13:738–747. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nakanishi C and Toi M: Nuclear
factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat
Rev Cancer. 5:297–309. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Asai T, Tomita Y, Nakatsuka S, et al: VCP
(p97) regulates NFkappaB signaling pathway, which is important for
metastasis of osteosarcoma cell line. Jpn J Cancer Res. 93:296–304.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Asai T, Ueda T, Itoh K, et al:
Establishment and characterization of a murine osteosarcoma cell
line (LM8) with high metastatic potential to the lung. Int J
Cancer. 76:418–422. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Knight DW: Feverfew: chemistry and
biological activity. Nat Prod Rep. 12:271–276. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu CA, Wang MJ, Chi CW, Wu CW and Chen
JY: Rho/Rhotekin-mediated NF-kappaB activation confers resistance
to apoptosis. Oncogene. 23:8731–8742. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shanmugam R, Jayaprakasan V, Gokmen-Polar
Y, et al: Restoring chemotherapy and hormone therapy sensitivity by
parthenolide in a xenograft hormone refractory prostate cancer
model. Prostate. 66:1498–1511. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang S, Won YK, Ong CN and Shen HM:
Anti-cancer potential of sesquiterpene lactones: bioactivity and
molecular mechanisms. Curr Med Chem Anticancer Agents. 5:239–249.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Koprowska K and Czyz M: Molecular
mechanisms of parthenolide’s action: old drug with a new face.
Postepy Hig Med Dosw (Online). 64:100–114. 2010.(In Polish).
|
|
16
|
Oka D, Nishimura K, Shiba M, et al:
Sesquiterpene lactone parthenolide suppresses tumor growth in a
xenograft model of renal cell carcinoma by inhibiting the
activation of NF-kappaB. Int J Cancer. 120:2576–2581. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wen J, You KR, Lee SY, Song CH and Kim DG:
Oxidative stress-mediated apoptosis. The anticancer effect of the
sesquiterpene lactone parthenolide. J Biol Chem. 277:38954–38964.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang S, Ong CN and Shen HM: Critical
roles of intracellular thiols and calcium in parthenolide-induced
apoptosis in human colorectal cancer cells. Cancer Lett.
208:143–153. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim JH, Liu L, Lee SO, Kim YT, You KR and
Kim DG: Susceptibility of cholangiocarcinoma cells to
parthenolide-induced apoptosis. Cancer Res. 65:6312–6320. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Guzman ML, Rossi RM, Karnischky L, et al:
The sesquiterpene lactone parthenolide induces apoptosis of human
acute myelogenous leukemia stem and progenitor cells. Blood.
105:4163–4169. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Griesenbach U, Meng C, Farley R, et al:
In vivo imaging of gene transfer to the respiratory tract.
Biomaterials. 29:1533–1540. 2008. View Article : Google Scholar
|
|
22
|
Wang CY, Mayo MW and Baldwin AS Jr: TNF-
and cancer therapy-induced apoptosis: potentiation by inhibition of
NF-kappaB. Science. 274:784–787. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mukogawa T, Koyama F, Tachibana M, et al:
Adenovirus-mediated gene transduction of truncated IkappaBalpha
enhances radiosensitivity in human colon cancer cells. Cancer Sci.
94:745–750. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Magne N, Toillon RA, Bottero V, et al:
NF-kappaB modulation and ionizing radiation: mechanisms and future
directions for cancer treatment. Cancer Lett. 231:158–168. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mauro C, Zazzeroni F, Papa S, Bubici C and
Franzoso G: The NF-kappaB transcription factor pathway as a
therapeutic target in cancer: methods for detection of NF-kappaB
activity. Methods Mol Biol. 512:169–207. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Eliseev RA, Zuscik MJ, Schwarz EM, O’Keefe
RJ, Drissi H and Rosier RN: Increased radiation-induced apoptosis
of Saos2 cells via inhibition of NF-kappaB: a role for c-Jun
N-terminal kinase. J Cell Biochem. 96:1262–1273. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mendonca MS, Chin-Sinex H, Gomez-Millan J,
et al: Parthenolide sensitizes cells to X-ray-induced cell killing
through inhibition of NF-kappaB and split-dose repair. Radiat Res.
168:689–697. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sun Y, St Clair DK, Fang F, et al: The
radiosensitization effect of parthenolide in prostate cancer cells
is mediated by nuclear factor-kappaB inhibition and enhanced by the
presence of PTEN. Mol Cancer Ther. 6:2477–2486. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kishida Y, Yoshikawa H and Myoui A:
Parthenolide, a natural inhibitor of nuclear factor-kappaB,
inhibits lung colonization of murine osteosarcoma cells. Clin
Cancer Res. 13:59–67. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Murphy JJ, Heptinstall S and Mitchell JR:
Randomised double-blind placebo-controlled trial of feverfew in
migraine prevention. Lancet. 2:189–192. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Miglietta A, Bozzo F, Gabriel L and Bocca
C: Microtubule-interfering activity of parthenolide. Chem Biol
Interact. 149:165–173. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sumner H, Salan U, Knight DW and Hoult JR:
Inhibition of 5-lipoxygenase and cyclooxygenase in leukocytes by
feverfew. Involvement of sesquiterpene lactones and other
components. Biochem Pharmacol. 43:2313–2320. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Patel NM, Nozaki S, Shortle NH, et al:
Paclitaxel sensitivity of breast cancer cells with constitutively
active NF-kappaB is enhanced by IkappaBalpha super-repressor and
parthenolide. Oncogene. 19:4159–4169. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sweeney CJ, Mehrotra S, Sadaria MR, et al:
The sesquiterpene lactone parthenolide in combination with
docetaxel reduces metastasis and improves survival in a xenograft
model of breast cancer. Mol Cancer Ther. 4:1004–1012. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Neelakantan S, Nasim S, Guzman ML, Jordan
CT and Crooks PA: Aminoparthenolides as novel anti-leukemic agents:
discovery of the NF-kappaB inhibitor, DMAPT (LC-1). Bioorg Med Chem
Lett. 19:4346–4349. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Guzman ML, Rossi RM, Neelakantan S, et al:
An orally bioavailable parthenolide analog selectively eradicates
acute myelogenous leukemia stem and progenitor cells. Blood.
110:4427–4435. 2007. View Article : Google Scholar
|
|
37
|
Shanmugam R, Kusumanchi P, Cheng L, et al:
A water-soluble parthenolide analogue suppresses in vivo
prostate cancer growth by targeting NF-kappaB and generating
reactive oxygen species. Prostate. 70:1074–1086. 2010.PubMed/NCBI
|
|
38
|
Shanmugam R, Kusumanchi P, Appaiah H, et
al: A water soluble parthenolide analog suppresses in vivo
tumor growth of two tobacco-associated cancers, lung and bladder
cancer, by targeting NF-kappaB and generating reactive oxygen
species. Int J Cancer. July 28–2010.(Epub ahead of print).
|
|
39
|
Yip-Schneider MT, Wu H, Ralstin M, et al:
Suppression of pancreatic tumor growth by combination chemotherapy
with sulindac and LC-1 is associated with cyclin D1 inhibition
in vivo. Mol Cancer Ther. 6:1736–1744. 2007. View Article : Google Scholar : PubMed/NCBI
|
